Traduction de «Beta-test a site » (Anglais → Français) :

It covers the entire chain of activities: from donation to procurement, testing, processing, preservation, storage and distribution to the site of medical use or to sites where manufactured products are made from these human substances.

(v) that, in the case of a test site situated within a space where a commercial or sporting activity occurs concurrently with the test, is delineated by walls or partitions in such a manner that the candidates are incapable of seeing anything outside the test site during the taking of the test except through a window;

This request was related to the following five points: chemical and biological weapons testing at the Gerstle River site of Alaska; transportation of replacement nuclear reactor cores to Fort Greely in 1964, 1965, 1966 and 1970; the March 1998 bunker bomb testing using depleted uranium bomb cases just across the border from Yukon; chemical weapons testing at Fort Wainright in the early 1990s; unexploded ordinance, nuclear waste storage, landfills and disposal sites at various points in Alaska.

(Return tabled) Question No. 199 Ms. Kirsty Duncan: With regard to the development and operation of the Canadian Multiple Sclerosis Monitoring System (CMSMS) announced in March 2011: (a) what are the government's baseline assumptions for the CMSMS, (i) how many Canadians live with MS according to the government’s source, (ii) what is the government's source; (b) what have been the challenges in developing the system between March 2011 and today, (i) how has each challenge been overcome, (ii) what are the achievements to date, (iii) what milestones has the government planned between December 2013 and December 2015 and by what dates; (c) what is the cost of developing the system, broken down by costs to date; (d) how much money did the Can ...[+++]adian Institutes for Health Research (CIHR) contribute to the development of the CMSMS, (i) were there any other partners involved in the development of the system, (ii) if so, who are they, (iii) what has each contributed; (e) who was involved in the design and development of the CMSMS, (i) from what departments/institutions were they, (ii) were potential conflicts of interest declared and, if so, how; (f) what health information does the CMSMS track, specifically, with regard to (i) chronic cerebrospinal venous insufficiency (CCSVI), (ii) impacts of CCSVI treatment, including but not limited to use of the following scales, Expanded Disability Status Scale, Modified Fatigue Impact Scale, Multiple Sclerosis Impact Scale, and Multiple Sclerosis Quality of Life Inventory, (iii) pharmaceutical treatments for MS, (vi) adverse drug reactions by MS drug; (g) who is/was overseeing pilot testing, (i) who is/was responsible for ensuring that patient information is/was protected, (ii) who is/was responsible for the integrity of the results; (h) were ethical reviews for pilot testing necessary and, if so, on what date did each pilot site pass ethical review; (i) when is pilot testing expected to/did it take place and at which MS clinics ...

The notified body shall have entrance for testing and verification purposes to the locations of design, building sites, production workshops, locations of assembly and installations, and where appropriate, prefabrication and testing facilities in order to carry out its tasks as provided for in the TSI.

It covers the entire chain of activities: from donation to procurement, testing, processing, preservation, storage and distribution to the site of medical use or to sites where manufactured products are made from these human substances.